IVI Provides Insight into CVS Health’s Decision to Include Cost-per-QALY Analyses from ICER into Formulary Decision-Making

2018-08-24T13:20:36+00:00August 17th, 2018|IVI News, Viewpoints|

CVS Health’s pharmacy benefit management (PBM) division, CVS Caremark, recently announced their decision to rely exclusively on the analyses of the Institute for Clinical and Economic (ICER) in a new drug management program. IVI’s Director of Scientific Communications, Mark Linthicum, responds to this story in MedCity stating, “The neat ‘answer’ regarding the value of treatment often overlooks vital information about sub-populations (e.g. ethnicities, age, gender, disease sub-type).”

Read Mark Linthicum’s full response in MedCity News here.

Read the CVS Health white paper, “Current and New Approaches to Making Drugs More Affordable” (2018), here.